Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome

被引:16
作者
Kalincik, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Guttmann, C. R. G. [8 ,9 ]
Krasensky, J. [3 ,10 ]
Vaneckova, M. [3 ,10 ]
Lelkova, P. [3 ,11 ]
Tyblova, M. [1 ,2 ,3 ]
Seidl, Z. [3 ,10 ]
De Jager, P. L. [4 ,12 ]
Havrdova, E. [1 ,2 ,3 ]
Horakova, D. [1 ,2 ,3 ]
机构
[1] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic
[3] Gen Univ Hosp Prague, Prague, Czech Republic
[4] Brigham & Womens Hosp, Dept Neurol, Program Translat NeuroPsychiat Genom, Boston, MA 02115 USA
[5] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Melbourne, Vic, Australia
[6] Univ Melbourne, Dept Neurol, Melbourne Brain Ctr, Melbourne, Vic, Australia
[7] Royal Melbourne Hosp, Melbourne, Vic, Australia
[8] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol,Ctr Neurol Imaging, Boston, MA 02115 USA
[9] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol,Ctr Neurol Imaging, Boston, MA 02115 USA
[10] Charles Univ Prague, Fac Med 1, Dept Radiol, Prague, Czech Republic
[11] Charles Univ Prague, Fac Med 1, Dept Pediat, Prague, Czech Republic
[12] Harvard Univ, Sch Med, Boston, MA USA
关键词
multiple sclerosis; susceptibility; prognosis; genotype; phenotype; MRI; HLA-DR; AGE; HLA-DR2; ALLELES; AZATHIOPRINE; PROGRESSION; INTERFERON; DIAGNOSIS; PHENOTYPE; SEVERITY;
D O I
10.1038/gene.2013.17
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
It has not yet been established whether genetic predictors of multiple sclerosis (MS) susceptibility also influence disease severity and accumulation of disability. Our aim was to evaluate associations between 16 previously validated genetic susceptibility markers and MS phenotype. Patients with clinically isolated syndrome verified by positive magnetic resonance imaging (MRI) and cerebrospinal fluid findings (n = 179) were treated with interferon-beta. Disability and volumetric MRI parameters were evaluated regularly for 2 years. Sixteen single-nucleotide polymorphisms (SNPs) previously validated as predictors of MS susceptibility in our cohort and their combined weighted genetic risk score (wGRS) were tested for associations with clinical (conversion to MS, relapses and disability) and MRI disease outcomes (whole brain, grey matter and white matter volumes, corpus callosum cross-sectional area, brain parenchymal fraction, T2 and T1 lesion volumes) 2 years from disease onset using mixed-effect models. We have found no associations between the tested SNPs and the clinical or MRI outcomes. Neither the combined wGRS predicted MS activity and progression over 2-year follow-up period. Power analyses confirmed 90% power to identify clinically relevant changes in all outcome variables. We conclude that the most important MS susceptibility loci do not determine MS phenotype and disease outcomes.
引用
收藏
页码:244 / 248
页数:5
相关论文
共 31 条
[1]   Multiple Sclerosis Risk Variant HLA-DRB1*1501 Associates with High Expression of DRB1 Gene in Different Human Populations [J].
Alcina, Antonio ;
del Mar Abad-Grau, Maria ;
Fedetz, Maria ;
Izquierdo, Guillermo ;
Lucas, Miguel ;
Fernandez, Oscar ;
Ndagire, Dorothy ;
Catala-Rabasa, Antonio ;
Ruiz, Agustin ;
Gayan, Javier ;
Delgado, Concepcion ;
Arnal, Carmen ;
Matesanz, Fuencisla .
PLOS ONE, 2012, 7 (01)
[2]   Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis [J].
Baranzini, Sergio E. ;
Wang, Joanne ;
Gibson, Rachel A. ;
Galwey, Nicholas ;
Naegelin, Yvonne ;
Barkhof, Frederik ;
Radue, Ernst-Wilhelm ;
Lindberg, Raija L. P. ;
Uitdehaag, Bernard M. G. ;
Johnson, Michael R. ;
Angelakopoulou, Aspasia ;
Hall, Leslie ;
Richardson, Jill C. ;
Prinjha, Rab K. ;
Gass, Achim ;
Geurts, Jeroen J. G. ;
Kragt, Jolijn ;
Sombekke, Madeleine ;
Vrenken, Hugo ;
Qualley, Pamela ;
Lincoln, Robin R. ;
Gomez, Refujia ;
Caillier, Stacy J. ;
George, Michaela F. ;
Mousavi, Hourieh ;
Guerrero, Rosa ;
Okuda, Darin T. ;
Cree, Bruce A. C. ;
Green, Ari J. ;
Waubant, Emmanuelle ;
Goodin, Douglas S. ;
Pelletier, Daniel ;
Matthews, Paul M. ;
Hauser, Stephen L. ;
Kappos, Ludwig ;
Polman, Chris H. ;
Oksenberg, Jorge R. .
HUMAN MOLECULAR GENETICS, 2009, 18 (04) :767-778
[3]   HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course [J].
Barcellos, LF ;
Oksenberg, JR ;
Begovich, AB ;
Martin, ER ;
Schmidt, S ;
Vittinghoff, E ;
Goodin, DS ;
Pelletier, D ;
Lincoln, RR ;
Bucher, P ;
Swerdlin, A ;
Perick-Vance, MA ;
Haines, JL ;
Hauser, SL .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (03) :710-716
[4]   Genome-wide association study of severity in multiple sclerosis [J].
Briggs, Farren B. S. ;
Shao, Xiaorong ;
Goldstein, Benjamin A. ;
Oksenberg, Jorge R. ;
Barcellos, Lisa F. ;
De Jager, Philip L. .
GENES AND IMMUNITY, 2011, 12 (08) :615-625
[5]   Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis [J].
Celius, EG ;
Harbo, HF ;
Egeland, T ;
Vartdal, F ;
Vandvik, B ;
Spurkiand, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 178 (02) :132-135
[6]   Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score [J].
De Jager, Philip L. ;
Chibnik, Lori B. ;
Cui, Jing ;
Reischl, Joachim ;
Lehr, Stephan ;
Simon, K. Claire ;
Aubin, Cristin ;
Bauer, David ;
Heubach, Juergen F. ;
Sandbrink, Rupert ;
Tyblova, Michaela ;
Lelkova, Petra ;
Havrdova, Eva ;
Pohl, Christoph ;
Horakova, Dana ;
Ascherio, Alberto ;
Hafler, David A. ;
Karlson, Elizabeth W. .
LANCET NEUROLOGY, 2009, 8 (12) :1111-1119
[7]   Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci [J].
De Jager, Philip L. ;
Jia, Xiaoming ;
Wang, Joanne ;
de Bakker, Paul I. W. ;
Ottoboni, Linda ;
Aggarwal, Neelum T. ;
Piccio, Laura ;
Raychaudhuri, Soumya ;
Tran, Dong ;
Aubin, Cristin ;
Briskin, Rebeccah ;
Romano, Susan ;
Baranzini, Sergio E. ;
McCauley, Jacob L. ;
Pericak-Vance, Margaret A. ;
Haines, Jonathan L. ;
Gibson, Rachel A. ;
Naeglin, Yvonne ;
Uitdehaag, Bernard ;
Matthews, Paul M. ;
Kappos, Ludwig ;
Polman, Chris ;
McArdle, Wendy L. ;
Strachan, David P. ;
Evans, Denis ;
Cross, Anne H. ;
Daly, Mark J. ;
Compston, Alastair ;
Sawcer, Stephen J. ;
Weiner, Howard L. ;
Hauser, Stephen L. ;
Hafler, David A. ;
Oksenberg, Jorge R. .
NATURE GENETICS, 2009, 41 (07) :776-U26
[8]   IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci [J].
Esposito, F. ;
Patsopoulos, N. A. ;
Cepok, S. ;
Kockum, I. ;
Leppa, V. ;
Booth, D. R. ;
Heard, R. N. ;
Stewart, G. J. ;
Cox, M. ;
Scott, R. J. ;
Lechner-Scott, J. ;
Goris, A. ;
Dobosi, R. ;
Dubois, B. ;
Rioux, J. D. ;
Oturai, A. B. ;
Sondergaard, H. B. ;
Sellebjerg, F. ;
Sorensen, P. S. ;
Reunanen, M. ;
Koivisto, K. ;
Cournu-Rebeix, I. ;
Fontaine, B. ;
Winkelmann, J. ;
Gieger, C. ;
Infante-Duarte, C. ;
Zipp, F. ;
Bergamaschi, L. ;
Leone, M. ;
Bergamaschi, R. ;
Cavalla, P. ;
Lorentzen, A. R. ;
Mero, I-L ;
Celius, E. G. ;
Harbo, H. F. ;
Spurkland, A. ;
Comabella, M. ;
Brynedal, B. ;
Alfredsson, L. ;
Bernardinelli, L. ;
Robertson, N. P. ;
Hawkins, C. P. ;
Barcellos, L. F. ;
Beecham, G. ;
Bush, W. ;
Cree, B. A. C. ;
Daly, M. J. ;
Ivinson, A. J. ;
Aubin, C. ;
Compston, A. .
GENES AND IMMUNITY, 2010, 11 (05) :397-405
[9]   Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial [J].
Filippi, M ;
Rovaris, M ;
Inglese, M ;
Barkhof, F ;
De Stefano, N ;
Smith, S ;
Comi, G .
LANCET, 2004, 364 (9444) :1489-1496
[10]   Risk alleles for multiple sclerosis identified by a genomewide study [J].
Hafler, David A. ;
Compston, Alastair ;
Sawcer, Stephen ;
Lander, Eric S. ;
Daly, Mark J. ;
De Jager, Philip L. ;
de Bakker, Paul I. W. ;
Gabriel, Stacey B. ;
Mirel, Daniel B. ;
Ivinson, Adrian J. ;
Pericak-Vance, Margaret A. ;
Gregory, Simon G. ;
Rioux, John D. ;
McCauley, Jacob L. ;
Haines, Jonathan L. ;
Barcellos, Lisa F. ;
Cree, Bruce ;
Oksenberg, Jorge R. ;
Hauser, Stephen L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :851-862